Contrasting Abbott Laboratories (ABT) & Its Peers

Abbott Laboratories (NYSE:ABT – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Abbott Laboratories to related companies based on the strength of its earnings, analyst recommendations, profitability, dividends, risk, institutional ownership and valuation.

Profitability

This table compares Abbott Laboratories and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Abbott Laboratories 9.75% 18.04% 9.09%
Abbott Laboratories Competitors -270.28% -155.47% -22.38%

Valuation & Earnings

This table compares Abbott Laboratories and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Abbott Laboratories $44.33 billion $6.52 billion 40.52
Abbott Laboratories Competitors $1.89 billion $136.81 million 5.72

Abbott Laboratories has higher revenue and earnings than its rivals. Abbott Laboratories is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Dividends

Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.3%. Abbott Laboratories pays out 94.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.1% and pay out 40.8% of their earnings in the form of a dividend. Abbott Laboratories has increased its dividend for 54 consecutive years.

Institutional and Insider Ownership

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Abbott Laboratories has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Abbott Laboratories’ rivals have a beta of 2.58, meaning that their average stock price is 158% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Abbott Laboratories and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abbott Laboratories 0 5 21 2 2.89
Abbott Laboratories Competitors 4310 10598 18377 838 2.46

Abbott Laboratories currently has a consensus price target of $118.32, suggesting a potential upside of 8.96%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.51%. Given Abbott Laboratories’ rivals higher probable upside, analysts plainly believe Abbott Laboratories has less favorable growth aspects than its rivals.

Summary

Abbott Laboratories beats its rivals on 11 of the 15 factors compared.

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.